NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Down 64.0% in March

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) was the recipient of a large drop in short interest in March. As of March 13th, there was short interest totaling 333,120 shares, a drop of 64.0% from the February 26th total of 926,133 shares. Based on an average daily volume of 388,359 shares, the days-to-cover ratio is currently 0.9 days. Approximately 2.2% of the company’s stock are short sold. Approximately 2.2% of the company’s stock are short sold. Based on an average daily volume of 388,359 shares, the days-to-cover ratio is currently 0.9 days.

Institutional Trading of NovaBay Pharmaceuticals

Several large investors have recently bought and sold shares of NBY. Ground Swell Capital LLC acquired a new position in NovaBay Pharmaceuticals during the 3rd quarter valued at approximately $25,000. Apollon Wealth Management LLC acquired a new stake in shares of NovaBay Pharmaceuticals during the third quarter worth $35,000. ExodusPoint Capital Management LP purchased a new stake in shares of NovaBay Pharmaceuticals during the fourth quarter valued at $114,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of NovaBay Pharmaceuticals during the fourth quarter valued at $120,000. Finally, C2C Wealth Management LLC acquired a new position in shares of NovaBay Pharmaceuticals in the 4th quarter valued at $254,000. Hedge funds and other institutional investors own 23.25% of the company’s stock.

NovaBay Pharmaceuticals Price Performance

Shares of NYSEAMERICAN:NBY opened at $1.50 on Wednesday. The business’s 50-day moving average is $10.61 and its 200 day moving average is $12.66. NovaBay Pharmaceuticals has a 1 year low of $1.11 and a 1 year high of $99.75. The firm has a market capitalization of $39.93 million, a P/E ratio of -0.15 and a beta of 0.25.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last issued its quarterly earnings results on Thursday, March 26th. The biopharmaceutical company reported ($7.60) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($7.40). On average, analysts expect that NovaBay Pharmaceuticals will post -2.54 EPS for the current year.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company’s synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay’s research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.

The company’s primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.